Iradimed (IRMD) Current Deferred Revenue (2013 - 2026)

Iradimed (IRMD) has 14 years of Current Deferred Revenue data on file, last reported at $7.2 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 23.34% year-over-year to $7.2 million in Q1 2026; TTM through Mar 2026 was $7.2 million, a 23.34% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, down 45.35% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $7.2 million, up from $2.9 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for IRMD reached as high as $7.2 million in Q1 2026 and fell as low as $1.6 million in Q3 2022.
• Historically, Current Deferred Revenue has averaged $3.1 million across 5 years, with a median of $2.6 million in 2023.
• On a YoY basis, Current Deferred Revenue climbed as much as 148.03% in 2025 and fell as far as 45.35% in 2025.
• Year by year, Current Deferred Revenue stood at $3.4 million in 2022, then declined by 23.8% to $2.6 million in 2023, then jumped by 104.36% to $5.3 million in 2024, then sank by 45.35% to $2.9 million in 2025, then jumped by 149.18% to $7.2 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $7.2 million in Q1 2026, $2.9 million in Q4 2025, and $3.2 million in Q3 2025.